Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$194.29 USD

194.29
4,749,724

-1.16 (-0.59%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $193.90 -0.39 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AbbVie (ABBV) Laps the Stock Market: Here's Why

by Zacks Equity Research

AbbVie (ABBV) closed at $154.88 in the latest trading session, marking a +0.17% move from the prior day.

AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion

by Zacks Equity Research

AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.

Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers

by Zacks Equity Research

Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.

Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B

by Zacks Equity Research

Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

The latest trading day saw AbbVie (ABBV) settling at $152.59, representing a +0.59% change from its previous close.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Ekta Bagri headshot

3 Biotech Stocks Most Wall Street Analysts Are Bullish About

by Ekta Bagri

Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for NOBL

AbbVie (ABBV) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $154.04, marking a -0.54% move from the previous day.

Here's How Much You'd Have If You Invested $1000 in AbbVie a Decade Ago

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod

by Kinjel Shah

AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.

The Zacks Analyst Blog Highlights AbbVie, NIKE, BHP Group, CME Group and Block

by Zacks Equity Research

AbbVie, NIKE, BHP Group, CME Group and Block are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for AbbVie, NIKE & BHP

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NIKE, Inc. (NKE) and BHP Group Ltd. (BHP).

AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B

by Zacks Equity Research

AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.

ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA

by Zacks Equity Research

The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.

Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DHS

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca

by Zacks Equity Research

Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More

by Kinjel Shah

AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

by Zacks Equity Research

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

Derek Lewis headshot

This Combination of 3 Stocks Provides Monthly Income

by Derek Lewis

Investors who select stocks in a structured manner can create a portfolio that pays them monthly. Who doesn't love payday?

AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study

by Zacks Equity Research

Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.

Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.

The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer

by Zacks Equity Research

AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as IBD Market Gains Traction

by Kinjel Shah

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).